Trade Novavax Inc - NVAX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.26 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 16.53 |
| Open | 16.53 |
| 1-Year Change | 107.92% |
| Day's Range | 16.53 - 17.62 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 16.69 | 1.49 | 9.80% | 15.20 | 17.42 | 14.39 |
| Jul 24, 2024 | 15.34 | -0.70 | -4.36% | 16.04 | 16.61 | 15.26 |
| Jul 23, 2024 | 16.09 | 1.40 | 9.53% | 14.69 | 16.42 | 14.54 |
| Jul 22, 2024 | 14.81 | 0.96 | 6.93% | 13.85 | 14.93 | 13.62 |
| Jul 19, 2024 | 13.85 | -0.54 | -3.75% | 14.39 | 14.96 | 13.75 |
| Jul 18, 2024 | 14.94 | -0.91 | -5.74% | 15.85 | 16.86 | 14.72 |
| Jul 17, 2024 | 15.84 | -0.96 | -5.71% | 16.80 | 16.84 | 15.16 |
| Jul 16, 2024 | 16.27 | 1.46 | 9.86% | 14.81 | 16.91 | 14.48 |
| Jul 15, 2024 | 15.17 | 2.07 | 15.80% | 13.10 | 15.23 | 13.10 |
| Jul 12, 2024 | 13.05 | -0.14 | -1.06% | 13.19 | 14.01 | 12.98 |
| Jul 11, 2024 | 12.85 | 1.09 | 9.27% | 11.76 | 12.95 | 11.50 |
| Jul 10, 2024 | 11.76 | 0.07 | 0.60% | 11.69 | 12.02 | 11.68 |
| Jul 9, 2024 | 11.71 | -0.08 | -0.68% | 11.79 | 12.16 | 11.68 |
| Jul 8, 2024 | 12.00 | 0.17 | 1.44% | 11.83 | 12.36 | 11.66 |
| Jul 5, 2024 | 11.87 | -0.67 | -5.34% | 12.54 | 12.61 | 11.67 |
| Jul 3, 2024 | 12.51 | -0.46 | -3.55% | 12.97 | 13.19 | 12.42 |
| Jul 2, 2024 | 12.69 | 0.01 | 0.08% | 12.68 | 13.10 | 12.49 |
| Jul 1, 2024 | 12.49 | -0.16 | -1.26% | 12.65 | 13.73 | 12.42 |
| Jun 28, 2024 | 12.61 | -0.23 | -1.79% | 12.84 | 12.99 | 12.29 |
| Jun 27, 2024 | 12.77 | -0.22 | -1.69% | 12.99 | 13.24 | 12.70 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Novavax Company profile
Novavax Inc. (NVAX) is a biotechnology company that specialises in the discovery, development and commercialisation of innovative vaccines that prevent serious infectious diseases.
Headquartered in Maryland, United States, the company was founded in 1987.
It has developed a number of vaccines, including:
The Coronavirus vaccine NVX-CoV2373, currently in phase 3 trials.
The seasonal Influenza vaccine NanoFlu™ for adults over the age of 65, currently also in phase 3 trials.
The respiratory Syncytial Virus (RSV) vaccine ResVax™ for infants and maternal immunisation, currently in phase 3 trials, as well as two RSV F Vaccines, one for older adults (phase 2 trials) and one for children until the age of 5 (phase 1 trials).
The Ebola Virus vaccine Ebola GP Vaccine, currently in phase 1 trials.
The company develops its vaccines using genetically engineered three-dimensional nanostructures of recombinant proteins that are critical to disease pathogenesis.
The company is also working on producing immune-stimulating adjuvants at its wholly owned Swedish subsidiary Novavax AB.
Navavax’s key partners and collaborators include:
The Coalition for Epidemic Preparedness Innovations (CEPI), which has been funding the company to develop and manufacture its coronavirus vaccine candidate.
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
The Serum Institute of India (SII).
The 2009 joint venture with India’s privately held pharmaceutical company, Cadila Pharmaceuticals Ltd, to develop Novavax VLP vaccine candidates and some Cadila therapeutic vaccine candidates.
The company (ticker: NVAX) went public on the NASDAQ stock exchange in 1995.
| Industry: | Biotechnology & Medical Research (NEC) |
700 Quince Orchard Road
GAITHERSBURG
MARYLAND 20878
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com